{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Confirmed positive ADA pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Confirmed positive ADA post-dose only"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Confirmed positive ADA at anytime"}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"}],"units":"Participants"}],"description":"Blood serum samples were collected and analysed to determine the presence or absence of ADA.\n\nADA is presented overall for all participants who received ADCT-402, as specified in protocol section 7.4.","groups":[{"description":"In Part 1 (dose escalation) participants received intravenous (IV) infusions of ADCT-402, at escalating doses according to a 3+3 study design. Doses assessed:\n\n* Dose Level 1: 15 μg/kg on Day 1 of each 3 week cycle (Q3W)\n* Dose Level 2: 30 μg/kg Day 1 Q3W\n* Dose Level 3: 60 μg/kg Day 1 Q3W\n* Dose Level 4: 90 μg/kg Day 1 Q3W\n* Dose Level 5: 120 μg/kg Day 1 Q3W\n* Dose Level 6: 150 μg/kg Day 1 Q3W\n* Dose Level 7: 200 μg/kg Day 1 Q3W and on Day 1 of each 6 week cycle (Q6W).\n\nIn Part 2 (expansion), participants received intravenous (IV) infusions of ADCT-402 at either 120 μg/kg or 150 μg/kg on Day 1 of each 3 week cycle (Q3W).","id":"OG000","title":"Parts 1 and 2: ADCT-402"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who were tested for ADA.","reportingStatus":"POSTED","timeFrame":"Q3W schedule: Day 1 to End of Cycle 1 (3 weeks); Q6W schedule: Day 1 to End of Cycle 1 (6 weeks)","title":"Number of Participants With Anti-drug Antibody Response (ADA) Against ADCT-402","type":"SECONDARY","unitOfMeasure":"Participants"}